Drug intelligence / Profile preview

TRA16

Development stage: Unknown
Lead developer: Wuhan Kangfude Biotechnology
Modality: Recombinant Proteins and Enzymes
Administration: Oral

Overview

TRA16 (also known as OxDc-A0) is a recombinant oxalate decarboxylase enzyme developed by Wuhan Kangfude Biotechnology (Kangfude Urolithiasis Institute) for the treatment of secondary hyperoxaluria. Administered orally, the enzyme is designed to be gastro-tolerant, allowing it to degrade dietary oxalate within the stomach and gastrointestinal tract. By reducing the available oxalate pool in the gut, TRA16 limits oxalate absorption into the bloodstream and subsequent urinary excretion, thereby potentially preventing the formation of calcium oxalate kidney stones and managing metabolic conditions associated with high oxalate levels. The drug has completed Phase 2 clinical trials in China and is being prepared for global Phase 3 development.

Other names: recombinant oxalate decarboxylase重组草酸脱羧酶

Beyond the preview

Go deeper on TRA16.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TRA16.

Explore the full profile